Inlecitug
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor) . Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers[1].
Product Specifications
CAS Number
2997627-68-4
UNSPSC
12352203
Target
VEGFR
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[Inlecitug]
References & Citations
[1]World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880177-500 1x 500 µL
CD50 (ICAM-3) (101-1D2), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402206-100 1x 100 µL
HSP60 (Heat Shock Protein 60) (Mitochondrial Marker) (HSPD1/2206R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details